Docoh
Loading...

CLVS Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe.

CLVS stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 21
24 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 230.2M 230.2M 230.2M 230.2M 230.2M 230.2M
Cash burn (monthly) (positive/no burn) 2.6M 22.15M 25.91M 15.59M 18.25M
Cash used (since last report) n/a 9.93M 84.48M 98.82M 59.44M 69.61M
Cash remaining n/a 220.28M 145.72M 131.38M 170.76M 160.59M
Runway (months of cash) n/a 84.6 6.6 5.1 11.0 8.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
4 Oct 21 Thomas C. Harding Common Stock Sell Dispose S Yes No 4.41 6 26.46 1,412
1 Oct 21 Thomas C. Harding Common Stock Option exercise Acquire M Yes No 0 15 0 1,418
1 Oct 21 Thomas C. Harding RSU Common Stock Option exercise Dispose M Yes No 0 15 0 172
2 Sep 21 Daniel W Muehl Common Stock Sell Dispose S No No 4.89 249 1.22K 61,364
2 Sep 21 Gillian C Ivers-read Common Stock Sell Dispose S No No 4.89 304 1.49K 254,980
2 Sep 21 Paul Edward Gross Common Stock Sell Dispose S No No 4.89 249 1.22K 55,318
2 Sep 21 Lindsey Rolfe Common Stock Sell Dispose S No No 4.89 347 1.7K 78,122
1 Sep 21 Daniel W Muehl Common Stock Option exercise Acquire M No No 0 563 0 61,613
1 Sep 21 Daniel W Muehl RSU Common Stock Option exercise Dispose M No No 0 563 0 1,125
1 Sep 21 Gillian C Ivers-read Common Stock Option exercise Acquire M No No 0 688 0 255,284

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

14.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 4 0 NEW
Opened positions 4 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 82.47M 0 NEW
Total shares 17.18M 0 NEW
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Highbridge Capital Management 9.91M $47.56M NEW
Palo Alto Investors 4.47M $21.45M NEW
Citadel Advisors 1.53M $7.34M NEW
Whitebox Advisors 1.28M $6.13M NEW
Capital World Investors 0 $0
Redmile 0 $0
Largest transactions
Shares Bought/sold Change
Highbridge Capital Management 9.91M +9.91M NEW
Palo Alto Investors 4.47M +4.47M NEW
Citadel Advisors 1.53M +1.53M NEW
Whitebox Advisors 1.28M +1.28M NEW
Capital World Investors 0 0
Redmile 0 0
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: ARPA, ATM, biallelic, Biden, block, BofA, breast, child, choice, colorectal, deprivation, derecognition, explore, extension, grow, Importantly, key, linked, lung, modified, Morgan, NaN, Nasdaq, ordinary, package, pancreatic, physician, President, prevailing, readout, repurpose, Rescue, ROU, stability, upcoming, usage
Removed: Assuming, enact, forthcoming, gene, lessen, observed